Coeheal
All articlesCancer Research

Mistletoe Therapy (Iscador): Europe's Most Used Cancer Adjunct

10 min readApril 27, 2026By M. Santos

Mistletoe extract is the most widely used complementary cancer therapy in Europe, prescribed by thousands of oncologists. Here's the evidence behind it.

Evidence qualityEmerging evidence — used in integrative oncology, not standard of care

Mistletoe extract (Iscador/Helixor) has a substantial European clinical literature as a cancer adjunct. Evidence quality is mixed; it is not a standard-of-care treatment in most countries.

For educational purposes only — not medical advice. How we evaluate evidence →

Part 4 of 9Cancer Research Series

Emerging natural compounds and protocols in integrative oncology.

Association data — causation not established

Epidemiological associations between high linoleic acid intake and some cancers exist, but causation has not been established. The seed oils and cancer hypothesis is contested and not accepted as mainstream evidence.

This article reviews the epidemiological data, the proposed mechanisms, and the limitations of the current evidence.

Always consult a qualified physician or oncologist before making any changes to your treatment plan. This article is for informational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation.

Written by

M. Santos

Health science researcher and medical writer

Reviewed by

Dr. A. Ferreira, MD

General practitioner with integrative medicine training. Reviewed for factual accuracy. Mistletoe extract is used as a cancer adjunct in integrative oncology; it is not a standard-of-care treatment.

Last reviewed

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Our editorial standards →

Mistletoe (Viscum album) extract — sold under brand names including Iscador, Helixor, and Eurixor — is the most widely used complementary cancer therapy in Europe, particularly in Germany, Switzerland, and Austria, where it is prescribed by conventional oncologists as an adjunct to standard cancer treatment. An estimated 60–80% of cancer patients in German-speaking countries use mistletoe therapy at some point during their treatment. This is not a fringe alternative therapy in the European context — it is mainstream integrative oncology.

The Active Compounds: Lectins and Viscotoxins

Mistletoe extract contains two primary classes of bioactive compounds: mistletoe lectins (ML-I, ML-II, ML-III) and viscotoxins. Mistletoe lectins are the most pharmacologically active components and have demonstrated multiple anticancer mechanisms in laboratory studies: induction of apoptosis in cancer cells, stimulation of natural killer (NK) cell activity, enhancement of dendritic cell function, and inhibition of tumor angiogenesis (the formation of new blood vessels that feed tumors). Viscotoxins have cytotoxic properties and may contribute to the immune-stimulating effects.

Clinical Evidence: Quality of Life and Survival

The clinical evidence for mistletoe therapy is more substantial than for most complementary cancer therapies, though still subject to significant methodological limitations. A 2020 Cochrane systematic review of 26 randomized controlled trials found that mistletoe therapy was associated with significant improvements in quality of life, fatigue, nausea, and overall wellbeing in cancer patients. Evidence for survival benefit is more limited and contested.

A landmark 2020 randomized controlled trial published in the European Journal of Cancer found that mistletoe extract (Iscador) significantly improved quality of life and reduced chemotherapy-related side effects in patients with advanced pancreatic cancer — one of the most difficult-to-treat malignancies. The mistletoe group also showed a non-significant trend toward improved survival. This trial is considered the highest-quality evidence to date for mistletoe therapy.

Administration and Dosing

Mistletoe therapy is typically administered as subcutaneous injections, 2–3 times per week, with doses gradually increased based on patient response. The dose is individualized based on the patient's reaction (a local skin reaction at the injection site is considered a sign of immune activation and is monitored). Treatment is typically continued throughout conventional cancer therapy and beyond. Oral and intravenous preparations also exist.

⚕️ Disclaimer: Mistletoe therapy should be used as an adjunct to, not a replacement for, conventional cancer treatment. It should be administered under the supervision of a qualified healthcare provider experienced in integrative oncology. Raw mistletoe plant is toxic and should never be consumed. This article is for educational purposes only.

Personalised plan

Healthy Aging Plan

Build a personalised plan for long-term health and prevention.

Get your personalised plan

Seen a claim you want to verify?

The Claim Decoder grades the evidence behind any natural health claim — A to F, with sources.

A— Strong RCTsB— Good evidenceC— Mixed studiesD— Weak evidenceF— No human data

Suggested from this article:

"High-dose vitamin C can treat cancer"

Prompted by: Mistletoe Therapy (Iscador): Europe's Most Used Cancer Adjunct